Moomoo AIのまとめ
Core Scientific has completed its private offering of $460 million 3.00% Convertible Senior Notes due 2029, including the full exercise of the initial purchasers' $60 million option. The notes will accrue interest at 3.00% per annum, payable semi-annually, with maturity on September 1, 2029. The initial conversion rate is 90.9256 shares per $1,000 principal amount, representing a conversion price of approximately $11.00 per share.The company will use approximately $61.2 million of the net proceeds to repay outstanding loans under its credit agreement and $150 million to redeem all outstanding 12.50% Secured Notes due 2028. The remaining proceeds will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.The notes include provisions for early conversion under specific circumstances and redemption options after September 7, 2027, subject to certain conditions. Core Scientific can settle conversions through cash, common stock, or a combination thereof at its discretion. The notes were offered to qualified institutional buyers under Rule 144A of the Securities Act.
Core Scientific has completed its private offering of $460 million 3.00% Convertible Senior Notes due 2029, including the full exercise of the initial purchasers' $60 million option. The notes will accrue interest at 3.00% per annum, payable semi-annually, with maturity on September 1, 2029. The initial conversion rate is 90.9256 shares per $1,000 principal amount, representing a conversion price of approximately $11.00 per share.The company will use approximately $61.2 million of the net proceeds to repay outstanding loans under its credit agreement and $150 million to redeem all outstanding 12.50% Secured Notes due 2028. The remaining proceeds will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions.The notes include provisions for early conversion under specific circumstances and redemption options after September 7, 2027, subject to certain conditions. Core Scientific can settle conversions through cash, common stock, or a combination thereof at its discretion. The notes were offered to qualified institutional buyers under Rule 144A of the Securities Act.
Core Scientificは、2029年満期の46,000万ドルの3.00%可換優先債を私募で完了しました。これには、初期購入者の6,000万ドルのオプションの全行使が含まれます。債券は年率3.00%の利息が付 accrualし、半期ごとに支払われ、2029年9月1日に満期を迎えます。初回の転換比率は、1,000ドルの元本に対して90.9256シェアで、転換価格はおおよそ11.00ドルです。会社は、純収益の約6120万ドルを与信契約の下での未払いローンの返済に使用し、15,000万ドルを2028年満期の全未払い12.50%担保債の償還に使用します。残りの収益は、運転資本、営業費用、資本支出...すべて展開
Core Scientificは、2029年満期の46,000万ドルの3.00%可換優先債を私募で完了しました。これには、初期購入者の6,000万ドルのオプションの全行使が含まれます。債券は年率3.00%の利息が付 accrualし、半期ごとに支払われ、2029年9月1日に満期を迎えます。初回の転換比率は、1,000ドルの元本に対して90.9256シェアで、転換価格はおおよそ11.00ドルです。会社は、純収益の約6120万ドルを与信契約の下での未払いローンの返済に使用し、15,000万ドルを2028年満期の全未払い12.50%担保債の償還に使用します。残りの収益は、運転資本、営業費用、資本支出、および潜在的な買収を含む一般的な企業目的に使用されます。債券には、特定の条件下での早期転換の条項と、2027年9月7日以降の償還オプションが含まれ、特定の条件が適用されます。Core Scientificは、転換を現金、普通株式、またはその組み合わせで裁量により精算できます。債券は、有価証券法の規則144Aの下で、資格のある機関投資家に提供されました。
役に立った
役に立たない
